Mankind Pharma Ltd News

Mankind Pharma inks licencing pact with Actimed for cachexia treatment

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

Stocks to Watch today, Nov 7: Bharti Airtel, LIC, Lupin, Bajaj Housing

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%

Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard

Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug

Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline

Mankind Pharma Q1 PAT drops 17.4% despite 24% revenue growth, costs surge

Input and finance costs weigh on profitability; chronic, consumer health and BSV acquisition support top line

Mankind Pharma Q1 results: Profit dips 17% to ₹445 cr; revenue rises

Mankind Pharma on Thursday reported a 17 per cent decline in consolidated profit after tax (PAT) at Rs 445 crore for the June quarter. The drug maker posted a PAT of Rs 538 crore for the April-June quarter of the last fiscal year. Revenue from operations rose to Rs 3,570 crore for the first quarter as compared to Rs 2,868 crore in the year-ago period, Mankind Pharma said in a statement. The company said its board has approved the raising of up to Rs 1,000 crore through unsecured funding instruments, including issuance of commercial papers, on a private placement basis, in one or more tranches. The board also approved interim dividend of Re 1 per share on face value of Re 1 per share for 2025-26. The company said its board has approved the acquisition of the branded generic business relating to women health portfolio of Bharat Serums and Vaccines Ltd through slump sale on a going concern basis. Shares of the company on Thursday ended 0.28 per cent down at Rs 2,567.75 apiece on the